The Chronic Granulomatous Disease drugs in development market research report provides comprehensive information on the therapeutics under development for Chronic Granulomatous Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Chronic Granulomatous Disease. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Chronic Granulomatous Disease and features dormant and discontinued products.
GlobalData tracks nine drugs in development for Chronic Granulomatous Disease by nine companies/universities/institutes. The top development phase for Chronic Granulomatous Disease is phase ii with four drugs in that stage. The Chronic Granulomatous Disease pipeline has six drugs in development by companies and three by universities/ institutes. Some of the companies in the Chronic Granulomatous Disease pipeline products market are: Pfizer, National Center for Child Health and Development and San Raffaele Scientific Institute.
The key targets in the Chronic Granulomatous Disease pipeline products market include Cytochrome b 245 Heavy Chain (CGD91 Phox or Cytochrome b558 Subunit Beta or Heme Binding Membrane Glycoprotein gp91phox or NADPH Oxidase 2 or Neutrophil Cytochrome b 91 kDa Polypeptide or Superoxide Generating NADPH Oxidase Heavy Chain Subunit or gp91-1 or p22 Phagocyte B Cytochrome or CYBB or EC 1.), Mast/Stem Cell Growth Factor Receptor Kit (Proto Oncogene c Kit or Tyrosine Protein Kinase Kit or v Kit Hardy Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog or Piebald Trait Protein or CD117 or KIT or EC 2.7.10.1), and Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2).
The key mechanisms of action in the Chronic Granulomatous Disease pipeline product include Cytochrome b 245 Heavy Chain (CGD91 Phox or Cytochrome b558 Subunit Beta or Heme Binding Membrane Glycoprotein gp91phox or NADPH Oxidase 2 or Neutrophil Cytochrome b 91 kDa Polypeptide or Superoxide Generating NADPH Oxidase Heavy Chain Subunit or gp91-1 o with two drugs in Phase I. The Chronic Granulomatous Disease pipeline products include five routes of administration with the top ROA being Intravenous and three key molecule types in the Chronic Granulomatous Disease pipeline products market including Gene-Modified Cell Therapy, and Monoclonal Antibody.
Chronic Granulomatous Disease overview
Chronic granulomatous disease (CGD) is a rare, inherited immunodeficiency that affects certain white blood cells called phagocytes and are unable to kill certain types of bacteria and fungi.
For a complete picture of Chronic Granulomatous Disease’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
